16837883

Source:http://linkedlifedata.com/resource/pubmed/id/16837883

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0020564, umls-concept:C0026727, umls-concept:C0034693, umls-concept:C0034786, umls-concept:C0042232, umls-concept:C0442805, umls-concept:C0529099, umls-concept:C0678227, umls-concept:C0963839, umls-concept:C1522492, umls-concept:C1522570, umls-concept:C2349975
pubmed:issue	4
pubmed:dateCreated	2006-7-18
pubmed:abstractText	Lasofoxifene, a new selective estrogen-receptor modulator (SERM), shows efficacy in vaginal and vulvar atrophy in postmenopausal women. Here, we sought to explore the possible mechanisms of action for this effect in comparison with other SERMs using an immature ovariectomized rat model.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9433353
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Estrogen Receptor beta, http://linkedlifedata.com/resource/pubmed/chemical/Ethinyl Estradiol, http://linkedlifedata.com/resource/pubmed/chemical/Pyrrolidines, http://linkedlifedata.com/resource/pubmed/chemical/Raloxifene, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Androgen, http://linkedlifedata.com/resource/pubmed/chemical/Selective Estrogen Receptor..., http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen, http://linkedlifedata.com/resource/pubmed/chemical/Tetrahydronaphthalenes, http://linkedlifedata.com/resource/pubmed/chemical/cis-1R-(4'-pyrrolidinoethoxyphenyl)-...
pubmed:status	MEDLINE
pubmed:issn	1072-3714
pubmed:author	pubmed-author:CosgrovePatricia GPG, pubmed-author:SalattoChristopher TCT, pubmed-author:SimmonsHollis AHA, pubmed-author:ThompsonDavid DDD, pubmed-author:WangXiao-NingXN
pubmed:issnType	Print
pubmed:volume	13
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	609-20
pubmed:meshHeading	pubmed-meshheading:16837883-Administration, Oral, pubmed-meshheading:16837883-Animals, pubmed-meshheading:16837883-Atrophy, pubmed-meshheading:16837883-Disease Models, Animal, pubmed-meshheading:16837883-Dose-Response Relationship, Drug, pubmed-meshheading:16837883-Estrogen Receptor beta, pubmed-meshheading:16837883-Ethinyl Estradiol, pubmed-meshheading:16837883-Female, pubmed-meshheading:16837883-Mucous Membrane, pubmed-meshheading:16837883-Ovariectomy, pubmed-meshheading:16837883-Postmenopause, pubmed-meshheading:16837883-Pyrrolidines, pubmed-meshheading:16837883-Raloxifene, pubmed-meshheading:16837883-Rats, pubmed-meshheading:16837883-Rats, Sprague-Dawley, pubmed-meshheading:16837883-Receptors, Androgen, pubmed-meshheading:16837883-Selective Estrogen Receptor Modulators, pubmed-meshheading:16837883-Tamoxifen, pubmed-meshheading:16837883-Tetrahydronaphthalenes, pubmed-meshheading:16837883-Uterus, pubmed-meshheading:16837883-Vagina, pubmed-meshheading:16837883-Vaginal Diseases
pubmed:articleTitle	Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
pubmed:affiliation	Pfizer Global Research and Development, Pfizer, Inc, Groton, CT 06340, USA. xiao.n.wang@pfizer.com
pubmed:publicationType	Journal Article